“Physicians need better therapy tools to treat Acute Heart Failure in the hospital. With the achievement of our Series A milestones and through subsequent work, our team has demonstrated that NeuroTronik CANS Therapy™ holds considerable promise to be a unique and valuable tool for physicians for use in this clinical setting,” said
NeuroTronik CANS Therapy™ is cardiac autonomic nerve stimulation delivered via a NeuroCatheter™, placed temporarily in a vein just above the heart, in combination with a NeuroModulator™, positioned bedside. The result of stimulation is enhanced cardiac output free of elevated heart rate.
“Our team has made substantial progress in the development of NeuroTronik CANS Therapy™,” said
The Series B Preferred Stock Financing is designed to resource the Company through to CE Mark approval of the NeuroTronik CANS Therapy™ System. About NeuroTronik NeuroTronik was founded in
Keywords for this news article include: Therapy, Hospital, Cardiology,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC